Antipsychotic drugs: Sudden cardiac death among elderly patients

Psychiatry (Edgemont)

Volumn 7, Issue 10, 2010, Pages 25-29

  Narang, Puneet ^a   El Refai, Mostafa ^b   Parlapalli, Roop ^b   Danilov, Lilia ^b   Manda, Sainath ^b   Kaur, Gagandeep ^b   Steven, Lippmann ^b  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Antipsychotic drugs; Dementiarelated psychoses; Geriatrics; Older people; Psychoses; QT interval; QT prolongation; Sudden cardiac death; Sudden death syndrome

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; HALOPERIDOL; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; PROCAINAMIDE; THIORIDAZINE; ZIPRASIDONE;

ADVERSE OUTCOME; AGED; ANXIETY DISORDER; CAUSE OF DEATH; CLINICAL EVALUATION; COMORBIDITY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMIC MONITORING; HUMAN; IMPULSE CONTROL DISORDER; INFORMATION DISSEMINATION; INSOMNIA; KINESIOTHERAPY; LOW DRUG DOSE; MANIA; METABOLIC DISORDER; METABOLIC SYNDROME X; NAUSEA; PAIN; PATIENT MONITORING; PERSONAL EXPERIENCE; PRESCRIPTION; PRIMARY HEALTH CARE; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QT INTERVAL; QT PROLONGATION; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH;

EID: 78650070438     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Data from U.S. Census Bureau, Population Division. http://www.census.gov/population/www/pop-profile/elderpop.html Accessed May 25, 2010.
2. IMS Health. 2008 U.S. Sales and Prescription Information (Top therapeutic classes by US sales). http://www.imshealth.com/portal/site/imshealth/menuitem.a953aef4d73d1ecd88f611019418c22a/?vgnextoid=bb967900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed May 25, 2010.
3. Maixner S, Mellow A, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psych. 1999;60(8):29-41.
4. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psych. 2001; 58, 1161-1167.
5. Wang P, Schneeweiss S, Avorn J, Fischer M. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2342.
6. Kuehn B. FDA warns antipsychotic drugs may be risky for elderly. JAMA. 2005;293(20):2462.
7. Gill S, Bronskill S, Rochon P. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786.
8. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
9. FDA (Drug Safety information for Antipsychotics: Postmarket Drug Safety Information for Patients and Providers). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084149.htm Accessed May 25, 2010.
10. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004; 164(12):1293-1297.
11. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-1671.
12. Cancro R, Wilder R. A mechanism of sudden death in chlorpromazine therapy. Am J Psych. 1970;127:368-371.
13. Weiner WJ, Goetz CG, Nausieda PA. Klawans HL. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med. 1980;92(3):444-450.
14. Modestin J, Krapf R, Boker W. A fatality during haloperidol treatment: mechanism of sudden death. Am J Psych. 1981;138:1616-1617.
15. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
16. Schneider L, Dagerman K, Insel P. The risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294(15):1934-1943.
17. Robinson D. Mortality risks and antipsychotics. Primary Psych. 2008;15(4):21-23.
18. Barak Y, Baruch Y, Mazeh D, et al. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psych. 2007;15(4):354-356.
19. Bauza PC, Sutor B. Clinical considerations for antipsychotic use in elderly patients with schizophrenia. Ann Longterm Care. 2009;17(9):26-30.
20. Alexopoulos G, Streim J, Carpenter D, Docherty J. Using antipsychotic agents in older patients. J Clin Psych. 2004;56(2):5-41.
21. Manalai P, Lippmann S. Antipsychotic drug cardio toxicity: will the QT interval forecast problems. The Kentucky Psychiatrist. 2007;18(1):8-9.
22. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.
23. Glassman A, Bigger T. Antipsychotic drugs: prolonged QT interval, Torsades de pointes, and sudden death. Am J Psych. 2001;158:1774-1782.
24. Kane J, Carson W. Efficacy and safety of aripiprazole and haloperidol versus placebo. J Clin Psych. 2002;63(9):763-771.
25. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):1-14.
26. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007; 298(15):1794-1796.
27. Rosenberg J, Woo D, Roane D. The aging patient with chronic schizophrenia. Ann Longterm Care. 2009;5:20-24.
28. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psych. 2001;58:565-572.
29. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psych. 2009;70(10):1340-1347.
30. Vieweg V. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5(5):205-215.